Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended 30th September, 2026 (Q2 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results and Corporate Action

Audit Opinion:

Clean opinion - No qualifications or modifications noted in the limited review reports by C. Sharat & Associates, Chartered Accountants.

Key Financial Highlights [₹ in Lakhs]:

Standalone Results:

Quarter Ended 30-09-2026 (Q2 FY27):

  • Revenue from Operations: ₹4,349.26
  • Total Income: ₹4,625.95
  • Net Profit: ₹410.19
  • EPS: ₹1.17 (Basic and Diluted)
  • Other Equity: ₹31,086.83 (as at 30-09-2026)
  • Cash and Cash Equivalents: ₹398.38
  • Debt: Total Borrowings ₹9,631.36 (Non-current ₹5,665.93 + Current ₹3,965.43)

Half Year Ended 30-09-2026 (H1 FY27):

  • Revenue from Operations: ₹8,440.46
  • Total Income: ₹9,071.91
  • Net Profit: ₹915.44
  • EPS: ₹2.62 (Basic and Diluted)

YoY Comparison (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: Increased 15% from ₹3,781.35
  • Net Profit: Decreased 53% from ₹871.57
  • EPS: Decreased from ₹2.64 to ₹1.17

Consolidated Results:

Quarter Ended 30-09-2026 (Q2 FY27):

  • Revenue from Operations: ₹5,021.50
  • Total Income: ₹5,237.40
  • Net Profit Attributable to Owners: ₹222.72
  • EPS: ₹0.64 (Basic and Diluted)
  • Other Equity: ₹25,358.42 (as at 30-09-2026)
  • Cash and Cash Equivalents: ₹569.08

Half Year Ended 30-09-2026 (H1 FY27):

  • Revenue from Operations: ₹9,509.39
  • Total Income: ₹10,014.98
  • Net Profit Attributable to Owners: ₹514.02
  • EPS: ₹1.47 (Basic and Diluted)

YoY Comparison (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: Increased 2.6% from ₹4,892.45
  • Net Profit Attributable to Owners: Decreased 73% from ₹818.97
  • EPS: Decreased from ₹2.49 to ₹0.64

Segment-wise Performance:

The Group is predominantly engaged in the pharmaceutical business, with no separate reporting segments as per Ind AS 108. The chief operating decision maker reviews the business as a single segment.

Corporate Actions:

The Board approved:

1. Conversion of entire outstanding debt (including service costs) aggregating up to ₹57.00 crore extended to Kilitch Estro Biotech PLC (KEB), a material subsidiary in Ethiopia, into equity shares of KEB, subject to FEMA and other applicable laws compliance.

2. Divestment of entire shareholding in KEB (including additional shares from the conversion) to HarmeeCare Pharmaceuticals, a state-owned public enterprise of the Oromia Regional State of Ethiopia, for an aggregate consideration of USD 14.00 million towards 100% shareholding and settlement of KEB's existing debts and liabilities.

3. Out of the total consideration, USD 12.855 million shall be payable to the Company.

4. The transaction is subject to applicable regulatory approvals and statutory compliances.

Other Significant Information:

Subsidiary Performance (as per auditor's report):

  • Kilitch Estro Biotech PLC (Ethiopian subsidiary): Q2 FY27 net loss of ₹246.90 lakhs, H1 FY27 net loss of ₹533.44 lakhs
  • Monarchy Healthserve Private Limited: Q2 FY27 net loss of ₹22.17 lakhs, H1 FY27 net loss of ₹44.01 lakhs

Balance Sheet Position (Standalone as at 30-09-2026):

  • Total Assets: ₹50,895.41 lakh
  • Total Equity: ₹34,582.99 lakh
  • Property, Plant and Equipment: ₹17,068.14 lakh
  • Investments: ₹12,913.84 lakh (Non-current ₹7,830.92 + Current ₹5,082.92)
  • Trade Receivables: ₹11,231.32 lakh

Cash Flow (Standalone H1 FY27):

  • Net cash from operating activities: ₹317.49 lakh
  • Net cash used in investing activities: ₹(1,439.70) lakh
  • Net cash from financing activities: ₹590.96 lakh
  • Net decrease in cash: ₹(531.25) lakh